131    Additional Definitions Clause Samples

131    Additional Definitions. The following table identifies the location of definitions set forth in various Sections of this Agreement: Accounting Firm 8.9(b)(i) Agreement Preamble Agreement Payments 8.10 Alliance Manager 3.7 Alternative Antibody Review Period 2.7(c) Anti-Corruption Laws 11.7(a)(i) Antitrust Filings 14.1 Bankrupt Party 14.3(d)(ii)(1) Biosimilar Applications 13.10(a) Biosimilar Reduction Trigger 8.5(c)(iii) Claim 12.1 CMO 6.1(a) Competitive Licensed Product 8.5(c)(iv) Controlling Party 13.10(a)(i) Data Package 2.11(b) Data Protection Laws 11.4(c) Development Matter 3.2(b) Development Plan 4.2 Dispute 15.5(a) Enforcement Action 13.3(b) Enforcing Party 13.3(b) Excluded Claim 15.5(e) Execution Date Preamble Global Development Plan 4.2 Global Safety Database 5.4(b) HKIAC 15.5(a) Indemnified Party 12.3 Indemnifying Party 12.3 Independent Activity Costs 5.3(c) Joint Patent Rights 13.1(c) JCMC 3.3(a) JDC 3.2(a) JSC 3.1 Losses 12.1 Manufacturing Dispute 3.3(c) Manufacturing Matter 3.3(c) New Clinical Trial 4.1(c) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. New Licensed Product Royalty Term 8.5(b)(iii) Non-Controlling Party 13.10(a)(i) Notice of Dispute 15.5(a) Objecting Party 3.5(c) Opt-In Date 2.11(b) Opt-In Notice 2.11(b) Opt-In Period 2.11(b) Opt-In Product Clinical Supply Agreement 6.2(a) Opt-In Product Commercial Supply Agreement 6.2(d) Opt-In Product Manufacturing Technology Transfer 6.2(b) Opt-In Product Technology Transfer Plan 6.2(b) Opt-In Product Royalty Term 8.5(b)(ii) Opt-In Right 2.11(a) Opt-In Product Third Party Payments 2.11(b) Opt-In Termination Territory 14.4(c)(i) Opt-In Terminated Product 14.4(c)(i) Party(ies) Preamble Patent Term Extension 13.5 Payee Party 8.4(b) Paying Party 8.4(b) Personal Data 11.4(c) Pharmacovigilance Agreement 5.4(a) Press Release 10.3(a) Prior CDAs 9.4 Product Infringement 13.3(a) Product Marks 13.8 Public Official 11.7(d) Publication 10.1(a) Purple Book 13.6 RC48 Clinical Supply Agreement 6.1(a) RC48 Commercial Supply Agreement 6.1(b)(i) RC48 Licensed Product Royalty Term 8.5(b)(i) RC48 Manufacturing Technology Transfer 6.1(b)(ii) RC48 Manufacturing Technology Transfer Plan 6.1(b)(ii) RC48 Terminated Product 14.4(b)(i) Remedial Action 5.6 RemeGen Preamble RemeGen Existing CMO Agreements 11.2(o) RemeGen Existing In-Licenses 11.2(v) [ * ] = CERTAIN CONFIDENTIAL ...
View SourceView Similar (2)

Related to 131    Additional Definitions

  • Additional Definitions The following terms have the meanings given below:

  • Additional Definition Section 1.02 of the Credit Agreement is hereby amended to add thereto in alphabetical order the following definition which shall read in full as follows:

  • Additional Defined Terms As used herein, the following defined terms shall have the following meanings with respect to the Notes only:

  • Special Definitions For purposes of this Section, the following specialized terms will have the following meanings:

  • SECTION I - DEFINITIONS As used in this Agreement, the following terms shall have the meanings ascribed herein unless otherwise stated or reasonably required by the Agreement, and other forms of any defined words shall have a meaning parallel thereto.